tenatoprazole and Epstein-Barr-Virus-Infections

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus responsible for several diseases, including cancers of lymphoid and epithelial cells. EBV cancers typically exhibit viral latency; however, the production and release of EBV through its lytic phase are essential for cancer development. Antiviral agents that specifically target EBV production do not currently exist. Previously, we reported that the proton pump inhibitor tenatoprazole, which blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV. Here, we show that three structurally distinct prazoles impair mature particle formation postreactivation and identify the impact on stages of replication. The prazoles did not impair expression of lytic genes representative of the different kinetic classes but interfered with capsid maturation in the nucleus as well as virion transport from the nucleus. Replacement of endogenous Tsg101 with a mutant Tsg101 refractory to prazole-mediated inhibition rescued EBV release. These findings directly implicate Tsg101 in EBV nuclear egress and identify prazoles as potential therapeutic candidates for conditions that rely on EBV replication, such as chronic active EBV infection and posttransplant lymphoproliferative disorders.

Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; A549 Cells; Antiviral Agents; Cell Line, Tumor; DNA-Binding Proteins; Endosomal Sorting Complexes Required for Transport; Epstein-Barr Virus Infections; HEK293 Cells; Herpesvirus 4, Human; Humans; Proton Pump Inhibitors; Rabeprazole; Transcription Factors; Viral Load; Virus Activation; Virus Latency; Virus Release; Virus Replication